Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide.

Purified outer membrane proteins and purified deacylated lipooligosaccharide (dLOS) were formulated for use as a vaccine in three formulations for clinical use. The three vaccine formulations included (1) purified outer membrane proteins (OMPs) and L8-5 dLOS adsorbed to aluminum hydroxide; (2) purified OMPs and L8-5 dLOS incorporated into liposomes; and (3) purified OMPs and L7 dLOS incorporated into proteoliposomes. The vaccines were compared for immunogenicity and safety in a phase 1clinical study.

Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice.

An ELISA-based assay is described for the measurement of antibodies to squalene (SQE) in human serum and plasma. The assay was adapted from the previously described assay for murine antibodies to SQE (J. Immunol.

Viral reservoirs/transient infection in HIV/AIDS: where are we now and where should we go? Summary of the June 13-14, 2002 Think Tank meeting.

Highly active antiretroviral therapy in individuals infected with human immunodeficiency virus (HIV) often lowers serum levels of virus to below current detection limits. However, cessation of therapy results in there appearance of virus replication, indicating that HIV-infected cells persist in such individuals. Identification, and elimination, of such reservoirs of virus-infected cells are crucial for eradicating HIV from infected individuals.